Our team will work closely with you to develop a personalized program that includes nutritional counseling, lifestyle modifications, and regular physical activity, helping you achieve lasting health improvements
Eli Lilly has already signaled its supply readiness by building a $1.5 billion inventory of orforglipron ahead of the anticipated FDA decision, a level of pre-approval investment that reflects confidence in both the approval and the commercial potential of the product
The results demonstrated that the 25mg daily pill delivered clinically meaningful weight loss: Average weight loss of 13.6-16.6% compared to 2.2-2.7% with placebo 76% of participants achieved at least 5% weight loss versus 31% on placebo Over 30% achieved 20% or greater weight loss Significant improvements in blood pressure, cholesterol, and inflammatory markers These results are comparable to what weve seen with injectable Wegovy, which typically produces 12-15% weight loss
Through one-on-one consultations, healthcare providers develop treatment plans tailored to each patients medical history, lifestyle, and how well they tolerate the medication
However, compounded tirzepatide ODT is not the same as FDA-approved injectable tirzepatide products
